139 related articles for article (PubMed ID: 38723281)
21. Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner.
Dimopoulos K; Søgaard Helbo A; Fibiger Munch-Petersen H; Sjö L; Christensen J; Sommer Kristensen L; Asmar F; Hermansen NEU; O'Connel C; Gimsing P; Liang G; Grønbaek K
Mol Oncol; 2018 Feb; 12(2):180-195. PubMed ID: 29130642
[TBL] [Abstract][Full Text] [Related]
22. Exploiting Protein Translation Dependence in Multiple Myeloma with Omacetaxine-Based Therapy.
Walker ZJ; Idler BM; Davis LN; Stevens BM; VanWyngarden MJ; Ohlstrom D; Bearrows SC; Hammes A; Smith CA; Jordan CT; Mark TM; Forsberg PA; Sherbenou DW
Clin Cancer Res; 2021 Feb; 27(3):819-830. PubMed ID: 33109736
[TBL] [Abstract][Full Text] [Related]
23. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma.
Zhu YX; Kortuem KM; Stewart AK
Leuk Lymphoma; 2013 Apr; 54(4):683-7. PubMed ID: 22966948
[TBL] [Abstract][Full Text] [Related]
24. Rapid Progress in the Use of Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in the Treatment of Multiple Myeloma.
Charliński G; Vesole DH; Jurczyszyn A
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572892
[TBL] [Abstract][Full Text] [Related]
25. Enhanced cross-priming of naive CD8+ T cells by dendritic cells treated by the IMiDs® immunomodulatory compounds lenalidomide and pomalidomide.
Henry JY; Labarthe MC; Meyer B; Dasgupta P; Dalgleish AG; Galustian C
Immunology; 2013 Jul; 139(3):377-85. PubMed ID: 23374145
[TBL] [Abstract][Full Text] [Related]
26. A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity.
Liu J; Song T; Zhou W; Xing L; Wang S; Ho M; Peng Z; Tai YT; Hideshima T; Anderson KC; Cang Y
Leukemia; 2019 Jan; 33(1):171-180. PubMed ID: 30026574
[TBL] [Abstract][Full Text] [Related]
27. USP15 antagonizes CRL4
Nguyen TV
Proc Natl Acad Sci U S A; 2021 Oct; 118(40):. PubMed ID: 34583995
[TBL] [Abstract][Full Text] [Related]
28. Homo-PROTACs for the Chemical Knockdown of Cereblon.
Steinebach C; Lindner S; Udeshi ND; Mani DC; Kehm H; Köpff S; Carr SA; Gütschow M; Krönke J
ACS Chem Biol; 2018 Sep; 13(9):2771-2782. PubMed ID: 30118587
[TBL] [Abstract][Full Text] [Related]
29. Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1.
Wu W; Nelson GM; Koch R; Donovan KA; Nowak RP; Heavican-Foral TB; Nirmal AJ; Liu H; Yang L; Duffy J; Powers F; Stevenson KE; Jones MK; Ng SY; Wu G; Jain S; Xu R; Amaka S; Trevisani C; Donaldson NL; Hagner PR; de Leval L; Gaulard P; Iqbal J; Thakurta A; Fischer ES; Adelman K; Weinstock DM
Blood; 2022 Mar; 139(13):2024-2037. PubMed ID: 34936696
[TBL] [Abstract][Full Text] [Related]
30. Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma.
Terpos E; Kanellias N; Christoulas D; Kastritis E; Dimopoulos MA
Onco Targets Ther; 2013; 6():531-8. PubMed ID: 23690693
[TBL] [Abstract][Full Text] [Related]
31. Single-Cell Proteomics and Tumor RNAseq Identify Novel Pathways Associated With Clofazimine Sensitivity in PI- and IMiD- Resistant Myeloma, and Putative Stem-Like Cells.
Kumar H; Mazumder S; Sharma N; Chakravarti S; Long MD; Meurice N; Petit J; Liu S; Chesi M; Sanyal S; Stewart AK; Kumar S; Bergsagel L; Rajkumar SV; Baughn LB; Van Ness BG; Mitra AK
Front Oncol; 2022; 12():842200. PubMed ID: 35646666
[TBL] [Abstract][Full Text] [Related]
32. IKAROS expression in distinct bone marrow cell populations as a candidate biomarker for outcome with lenalidomide-dexamethasone therapy in multiple myeloma.
Bolomsky A; Hübl W; Spada S; Müldür E; Schlangen K; Heintel D; Rocci A; Weißmann A; Fritz V; Willheim M; Zojer N; Palumbo A; Ludwig H
Am J Hematol; 2017 Mar; 92(3):269-278. PubMed ID: 28052520
[TBL] [Abstract][Full Text] [Related]
33. Involvement of EZH2 inhibition in lenalidomide and pomalidomide-mediated growth suppression in HTLV-1-infected cells.
Kondo N; Nagano Y; Hasegawa A; Ishizawa M; Katagiri K; Yoneda T; Masuda T; Kannagi M
Biochem Biophys Res Commun; 2021 Oct; 574():104-109. PubMed ID: 34455369
[TBL] [Abstract][Full Text] [Related]
34. Role of IRF4 in resistance to immunomodulatory (IMid) compounds
Bertrand E; Jouy N; Manier S; Fouquet G; Guidez S; Boyle E; Noel S; Tomowiak C; Herbaux C; Schraen S; Preudhomme C; Quesnel B; Poulain S; Leleu X
Oncotarget; 2017 Dec; 8(68):112917-112927. PubMed ID: 29348877
[TBL] [Abstract][Full Text] [Related]
35. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.
Zhu YX; Braggio E; Shi CX; Bruins LA; Schmidt JE; Van Wier S; Chang XB; Bjorklund CC; Fonseca R; Bergsagel PL; Orlowski RZ; Stewart AK
Blood; 2011 Nov; 118(18):4771-9. PubMed ID: 21860026
[TBL] [Abstract][Full Text] [Related]
36. Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma.
Gooding S; Ansari-Pour N; Kazeroun M; Karagoz K; Polonskaia A; Salazar M; Fitzsimons E; Sirinukunwattana K; Chavda S; Ortiz Estevez M; Towfic F; Flynt E; Pierceall W; Royston D; Yong K; Ramasamy K; Vyas P; Thakurta A
Blood; 2022 Oct; 140(16):1816-1821. PubMed ID: 35853156
[TBL] [Abstract][Full Text] [Related]
37. Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs.
Lindner S; Steinebach C; Kehm H; Mangold M; Gütschow M; Krönke J
J Vis Exp; 2019 May; (147):. PubMed ID: 31157769
[TBL] [Abstract][Full Text] [Related]
38. The CRBN, CUL4A and DDB1 Expression Predicts the Response to Immunomodulatory Drugs and Survival of Multiple Myeloma Patients.
Barankiewicz J; Szumera-Ciećkiewicz A; Salomon-Perzyński A; Wieszczy P; Malenda A; Garbicz F; Prochorec-Sobieszek M; Misiewicz-Krzemińska I; Juszczyński P; Lech-Marańda E
J Clin Med; 2021 Jun; 10(12):. PubMed ID: 34207079
[TBL] [Abstract][Full Text] [Related]
39. Immunomodulatory drugs in the treatment of multiple myeloma.
Abe Y; Ishida T
Jpn J Clin Oncol; 2019 Aug; 49(8):695-702. PubMed ID: 31187860
[TBL] [Abstract][Full Text] [Related]
40. [Association of CRBN Gene with Immunomodulatory Drug Resis- tance in Multiple Myeloma].
Cai QQ; Li J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Jun; 23(3):892-7. PubMed ID: 26117057
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]